A Study of RC118 Plus Toripalimab / RC148 in Patients with Locally Advanced Unresectable or Metastatic Solid Tumors — StellaPhase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(18 sites)
China
Fujian Cancer Hospital, Fuzhou, Fujian The First Affiliated Hospital of Xiamen University, Xiamen, Fujian Gansu Wuwei Tumour Hospital, Wuwei, Gansu Meizhou People's Hospital, Meizhou, Guangdong Harbin Medical University Cancer Hospital, Harbin, Heilongjiang Nanyang Central Hospital, Nanyang, Henan Xinyang Central Hospital, Xinyang, Henan The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu Xuzhou Central Hospital, Xuzhou, Jiangsu The First Affiliated Hospital of Bengbu Medical University, Bengbu, Shandong Cancer Hospital of Shandong First Medical University, Jinan, Shandong Changzhi People's Hospital, Changzhi, Shanxi West China Hospital Sichuan University, Chengdu, Sichuan The Second People's Hospital of Neijiang, Neijiang, Sichuan Zhejiang Cancer Hospital, Hangzhou, Zhejiang The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang Zhongshan Hospital Fudan University, Shanghai Last updated January 2025